astellas

Astellas Broadens Commitment to Clinical Trial Data Transparency

Press Release

TOKYO, Feb. 2, 2015 /3BL Media/ - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an independent Web site that enables researchers to request and access clinical trial data after approval of a research proposal by an independent review panel.

Pharma Innovation Faces New Challenges And Presents New Solutions In 2015

Astellas to Present at J.P. Morgan Healthcare Conference
Multimedia with summary

The top players in the pharmaceutical industry are heading to the 33rd Annual J.P. Morgan Healthcare Conference this week to revisit the many successes of 2014, and to better understand what challenges and opportunities the industry will face in 2015. Although budgets are shrinking, the changing healthcare landscape presents many opportunities to further develop innovative medicines for patients.

Astellas Named to FTSE4Good Sustainability Index for the Third Year

Press Release

December 9, 2014 /3BL Media/ - Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the third year to be included in the FTSE4Good Index, one of the world’s premier indexes for socially responsible investment.

Astellas Named a 2015 Best Place to Work for Lesbian, Gay, Bisexual and Transgender Equality

Company Receives Perfect Score on Human Rights Campaign’s Corporate Equality Index
Press Release

NORTHBROOK, Ill., Nov. 19, 2014 /3BL Media/ – Astellas, a leading pharmaceutical company, received a perfect score on the Human Rights Campaign’s (HRC) annual Corporate Equality Index (CEI).  The CEI is a national benchmarking tool used to rate companies on policies and practices concerning lesbian, gay, bisexual and transgender (LGBT) employee equality.

Pages

Subscribe to astellas